1449 GMT - French drugmaker Sanofi and U.S. partner Regeneron Pharmaceuticals could extend the U.S. patent on their blockbuster anti-inflammatory drug Dupixent by two years to 2033, RBC Capital Markets analysts write in a research note. RBC sees a 70% chance of this happening and says the move could help Sanofi as it reshapes its portfolio. "Sanofi is navigating a pivotal transition amid near-term challenges," the analysts say. Despite Dupixent's strength, investors want proof of diversified growth and acquisitions seem likely, they add. RBC starts coverage of Sanofi with a sector perform recommendation and a target price of 80 euros. Shares fall 0.9% to 74.05 euros.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.